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MATERIALS 
Fmoc-D-X-OH (Fmoc, fluoren-9-ylmethoxycarbonyl) (X = Ala, Arg(Pbf) (Pbf, 
pentamethyldihydrobenzofuran-5-sulfonyl), Asn(Trt) (Trt, trityl), Asp(OtBu) (tBu, tert-butyl), 
Glu(OtBu), Gln(Trt), Gly, His(Trt), Ile, Leu, Lys(Boc) (Boc, tert-butyloxycarbonyl), Met, Phe, 
Pro, Ser(tBu), Thr(tBu), Trp(Boc), Tyr(tBu), and Val) were purchased (Anaspec; San Jose, CA) 
and used as received. TentaGel S-NH2 resin (90 μm, 0.31 mmol/g) (Rapp-Polymere; Tübingen, 
Germany) were utilized for OBOC library construction.  Amino acid coupling reactions were 
performed in 1-methyl-2-pyrrolidinone (NMP, 99%) with HATU (2-(7-Aza-1H-benzotriazole-1-
yl)-1,1,3,3-tetramethylammonium hexafluorophosphate, ChemPep; Miami, FL) and N,N′-
diisopropylethylamine (DIEA).  For removal of Nα-Fmoc protecting groups, a solution of 20% 
piperidine in NMP was used.  For final deprotection of the peptide libraries, trifluoroacetic acid 
(TFA, 98% min. titration) and triethylsilane (TES) were used.  All solvents and reagents were 
purchased from Sigma-Aldrich (St. Louis, MO) and used as received, unless otherwise noted. 
 OBOC libraries were synthesized using a 180-degree variable-speed shaker, fitted with 
small sample adapter (St. John Associates; Beltsville, MD).  Fritted polypropylene solid-phase 
synthesis tubes were used for repeated split-mix cycles.  A 24-port SPE vacuum manifold system 
(Grace, Deerfield, IL) was used for exchanging coupling solutions and washing the resins. 
Fmoc-D-propargylglycine (Fmoc-D-Pra-OH) was acquired (Chem-Impex International; 
Wood Dale, IL) and used as the acetylene handle for construction of ligands. 
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Proteins.  Bovine carbonic anhydrase II (bCAII, C2522), from bovine erythrocytes, 
lyophilized powder, was obtained (Sigma-Aldrich; St. Louis, MO) and used as received.  To 
prepare the protein for screening, dye-labeling was accomplished with the Alexa Fluor 647 
Microscale Protein Labeling Kit (Invitrogen; Carlsbad, CA) following the manufacturer’s 
protocol for a low degree of labeling (DOL).  Protein (100 μg) was incubated with 6 mol equiv 
Alexa Fluor 647 succinimidyl ester for 15 min at 25 °C.  Excess dye was removed by BioGel P-6 
size exclusion resin (Bio-Rad, Hercules, CA).  The labeled protein (bCAII-Alexa Fluor 647) was 
characterized by UV-Vis and mass spectrometry. 
Human carbonic anhydrase II (hCAII, C6165), from human erythrocytes, lyophilized 
powder, was obtained (Sigma-Aldrich; St. Louis, MO) and used in affinity and selectivity 
studies.  Both bCAII and hCAII were tested by SDS gel electrophoresis, and confirmed to 
display a single band corresponding to 29,000 Da. 
 
ARTIFICIAL AMINO ACID SYNTHESIS (SCHEME S1) 
Azidobutylbromide (1a).  To a solution of 1,4-dibromobutane (123 mmol), sodium 
azide (61.5 mmol) was added and stirred overnight in N,N′-dimethylformamide (DMF) at 50 °C. 
The reaction was diluted 
with ethyl acetate, and the 
organic layer was washed 
with water, then brine, and 
then dried over MgSO4.  The 
crude residue was purified by 
silica gel chromatography 
(100% hexanes) to give a 
product (80%) as a clear oil.  
1H NMR (300 MHz, CDCl3): 
δ 3.44 (2H, t, J = 6.3 Hz), 3.34 (2H, t, J = 6.6 Hz), 1.93-1.98 (2H, m), 1.74-1.79 (2H, m). 
SCHEME S1 
Azidooctylbromide (1b).  Synthesis was carried out as described above, except 1,8-
dibromooctane was used as the starting material.  1H NMR (300 MHz, CDCl3): δ 3.41 (2H, t, J = 
6.9 Hz), 3.26 (2H, t, J = 6.6 Hz), 1.86 (2H, p, J = 6.9 Hz), 1.60 (2H, p, J = 8.7 Hz), 1.34-1.55 
(4H, m). 
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Diethyl 2-acetamido-2-(4-azidobutyl)malonate (2a).  To a solution of 0.598 g (0.026 
mol) sodium metal in 25 mL absolute EtOH, 5.65 g diethyl acetamidomalonate (0.026 mol) was 
added, following previously published procedures.[1]  The mixture was stirred for 30 min at room 
temperature.  By dropwise addition, azidobutylbromide 1a (4.82 g, 0.027 mol) was added with 
stirring.  The reaction mixture was stirred for 2 h at room temperature and refluxed for 6 h at 80 
°C.  After cooling overnight, the reaction mixture was concentrated to dryness, and the residue 
was extracted with diethyl ether.  The combined ether extracts were washed with water, sat. 
NaHCO3, water, and brine, and were dried over MgSO4 and then concentrated.  Silica gel 
chromatography (Hex:EtOAc = 1:1) gave a product (63%) as a clear, viscous oil.  1H NMR (300 
MHz, CDCl3): δ 6.77 (1H, s), 4.24 (4H, q, J = 6.9 Hz), 3.26 (2H, t, J = 6.9 Hz), 2.31-2.37 (2H, 
m), 2.04 (3H, s), 1.59 (2H, p, J = 7.5 Hz), 1.26 (6H, t, J = 6 Hz), 1.16-1.27 (2H, m).  ESI-MS 
m/e 315. 
Diethyl 2-acetamido-2-(4-azidooctyl)malonate (2b).  Similar synthetic protocol as 2a 
was adopted, only azidooctylbromide 1b served as the starting material.  1H NMR (300 MHz, 
CDCl3): δ 6.76 (1H, s), 4.24 (4H, q, J = 7.2 Hz), 3.24 (2H, t, J = 6.9 Hz), 2.27-2.33 (2H, m), 2.04 
(3H, s), 1.56 (2H, p, J = 7.5 Hz), 1.25 (6H, t, J = 7.2 Hz), 1.06-1.16, 1.2-1.4 (10H, m).  ESI-MS 
m/e 371. 
2-Azidobutyl amino acid (3a).  Following standard methods,[2] the diester 2a (2.8 mmol) 
in 25 mL of 10% NaOH solution was heated to reflux for 4 h.  The solution was then neutralized 
with concentrated HCl and evaporated.  The residue was dissolved in 25 mL of 1 M HCl and 
heated to reflux for 3 h.  The solvent was reduced and extraction with MeOH afforded amino 
acid 3a as the hydrochloride salt (85%).  1H NMR (300 MHz, CD3OD): δ 3.98 (1H, t, J = 6.3 
Hz), 3.35 (2H, t, J = 7.8 Hz), 1.45-1.7, 1.85-2.05 (6H, m).  MALDI-MS m/e 173. 
2-Azidooctyl amino acid (3b).  Synthesis was carried out as described above, using 
diester 2b as the starting material.  1H NMR (300 MHz, CD3OD): δ 3.94 (1H, t, J = 6.3 Hz), 3.27 
(2H, t, J = 6.9 Hz), 1.3-1.52, 1.52-1.62, 1.8-1.98 (14H, m).  ESI-MS m/e 229. 
Fmoc-2-Azidobutyl amino acid (Fmoc-Az4-OH).  The amino acid 3a (26.3 mmol) was 
dissolved in 0.45:0.55 H2O:THF (150 mL), and NaHCO3 (22.1 g, 263 mmol) was added, 
following published methods.[3]  After the mixture was cooled to 0 °C, Fmoc-OSu (9.7 g, 28.9 
mmol) was added dropwise over 5 min.  The reaction mixture was allowed to come to room 
temperature and stirred overnight.  Evaporation of THF was completed in vacuo and the aqueous 
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residue was washed with diethyl ether (2 × 200 mL).  The aqueous layer was then collected and 
acidified with conc. HCl to pH 2 before extraction with ethyl acetate (4 × 100 mL).  The 
combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated.  
The organic residue was purified by column chromatography (2% MeOH in DCM) to yield a 
white powder (48% yield).  1H NMR (300 MHz, CDCl3): δ 7.76 (2H, d, J = 7.5 Hz), 7.59 (2H, d, 
J = 6.9 Hz), 7.40 (2H, t, J = 7.5 Hz), 7.31 (2H, t, J = 7.5 Hz), 5.34 (1H, d, J = 7.8 Hz), 4.49-4.59 
(1H, m), 4.43 (2H, d, J = 6.6 Hz), 4.22 (1H, t, J = 6.6 Hz), 3.27 (2H, t, J = 6.6 Hz), 1.3-2.0 (6H, 
m).  ESI-MS m/e 395. 
Fmoc-2-Azidooctyl amino acid (Fmoc-Az8-OH).  The amino acid 3b was treated to 
Fmoc protection as described above.  1H NMR (300 MHz, CDCl3): δ 7.75 (2H, d, J = 7.5 Hz), 
7.57-7.61 (2H, m), 7.39 (2H, t, J = 7.5 Hz), 7.30 (2H, t, J = 7.2 Hz), 5.40 (1H, d, J = 8.1 Hz), 
4.42-4.52 (1H, m), 4.40 (2H, d, J = 7.2 Hz), 4.21 (1H, t, J = 7.2 Hz), 3.23 (2H, t, J = 6.9 Hz), 
1.18-1.98 (14H, m).  ESI-MS m/e 450. 
 
PEPTIDE LIBRARY CONSTRUCTION 
Randomized OBOC libraries of penta- to heptapeptides were synthesized manually via 
standard split-and-mix solid-phase peptide synthesis methods on 90 µm polyethylene glycol-
grafted polystyrene beads (TentaGel S-NH2, 0.31 mmol/g, 2.86 x 106 beads/g).[4-6]  Non-natural 
D-stereoisomers (denoted by lowercase one-letter amino acid code) were used at every possible 
position in the peptide sequence.  At least a 5-fold excess of beads was utilized in each library 
synthesis to ensure adequate representation of each library element.  A standard solid-phase 
peptide synthesis method with Fmoc chemistry was used.[7]  All wash, deprotection, and 
coupling steps were facilitated by 180-degree shaking of the resin.  The resin was pre-swelled in 
NMP in a plastic fritted reaction vessel, and was separated into multiple aliquots.  Each aliquot 
was reacted with 2-fold molar excess (relative to resin) of a single Nα-Fmoc-amino acid.  Amide 
coupling was initiated by addition of a 2-fold molar excess of HATU and a 6-fold molar excess 
of DIEA.[8]  The coupling reaction was run for 15 min.  Another 2 equiv Nα-Fmoc-amino acid, 2 
equiv HATU, and 6 equiv DIEA were added, and allowed to react for 15 min (“double 
coupling”).  In some cases, “triple coupling” with a third set of coupling reagents and Nα-Fmoc-
amino acid was performed (Table S1, Libraries D, E, F, and G).  Following coupling, the 
aliquots were thoroughly washed (5 × NMP), mixed together into a single vessel, and 
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deprotected with 20% piperidine in NMP (30 min).  The resin was thoroughly washed (5 × 
NMP), dried (5 × DCM), and re-divided into multiple equal-mass aliquots for the next cycle of 
coupling.  The procedures were repeated until the desired length of peptide was attained. 
Table S1.  Libraries used in this study.† 
 Formula Components # of unique 
sequences 
A x1x2x3x4x5 xi = 19 D-amino acids 
(no D-Cys) 
2,476,099 
B x1x2x3x4x5x6 xi = r, k, l, w, f, h, y 117,649 
C Azn-x2x3x4x5x6-Azn xi = 19 D-amino acids 
(no D-Cys) 
Azn = 1/3 Az4, 1/3 Az8, 
1/3 nothing 
22,284,891 
D x1x2x3x4x5x6-Tz1-kfwlkl xi = k, l, w, f, i, g, v 117,649 
Tz1 = triazole formed between Az4 (on terminal k) and D-Pra (on x6) 
E x7x6x5x4x3x2-Tz2-kwlwGl-
Tz1-kfwlkl 
xi = d, r, s, w, G, f, l 117,649 
Tz1 = triazole formed between Az4 (on terminal k) and D-Pra (on l) 
Tz2 = triazole formed between Az4 (on terminal x2) and D-Pra (on k) 
F Az4-x2x3x4x5x6x7 3200 
G x7x6x5x4x3x2-Tz2-kwlwGl-
Tz1-kfwlkl 
x2 = r, n, l, i; 
x3 = w, f, l, i; 
x4 = r, w, f, l, i; 
x5 = w, f, v, l; 
x6 = r, w, f, l, k; 
x7 = f, r 
3200 
† Randomized positions are denoted by x (for D-amino acids) and Azn (for azide-
containing artificial amino acids). 
The amino acid side-chain protecting groups were then removed by incubation in 
trifluoroacetic acid (95%), water (5%), and triethylsilane (2-fold molar excess per protected side 
chain) for 2 h at 25 °C.  The library resin was then neutralized with DMF, and washed 
thoroughly with DMF (5 ×), water (5 ×), methanol (MeOH, 5 ×), and methylene chloride (DCM, 
5 ×),[9] and then dried under vacuum and stored in phosphate-buffered saline [PBS (pH 7.4)] + 
0.05% NaN3 at 25 °C. 
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BULK PEPTIDE SYNTHESIS 
Bulk synthesis of hit peptide sequences was performed on either Fmoc-Rink amide 
MBHA (50 μm, 0.67 mmol/g) or 2-chlorotrityl chloride (1.5 mmol/g) resins (Anaspec; San Jose, 
CA), on a typical resin scale of 0.3 g per sequence.  Crude peptides were precipitated with ether, 
and then purified to >98% by HPLC (Beckman Coulter System Gold 126 Solvent Module and 
168 Detector, Fullerton, CA) on a C18 reversed phase semi-preparative column (Phenomenex 
Luna 10 µm, 250 × 10 mm).  The pure peptides were used for affinity measurements, screens, 
and binding assays.  Hit peptide sequences were also re-synthesized on TentaGel S-NH2 on a 
similar resin scale, and used for on-bead binding assays. 
 
ON-BEAD CLICK REACTION 
For preparing Libraries D, E, and G (Table S1), as well as for bulk synthesis of biligand 
and triligand candidates, the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) was carried 
out on bead, with 4 general steps: (1) anchor ligand synthesis, (2) acetylation, (3) click reaction, 
and (4) addition of 2° ligand sequence.  Scheme S2 illustrates the acetylation and click reactions 
for a 6-mer peptide (Z = any amino acid).  The fully protected TentaGel S-NH2 bead-bound 
anchor ligand (0.420 g, 0.13 mmol) was 
capped by a solution of acetic anhydride (1 
mmol) in 2,6-lutidine and DMF.[10]  The 
acetylated peptide was reacted with Fmoc-
D-Pra-OH (0.218 g, 0.65 mmol) in the 
presence of CuI (0.124 g, 0.65 mmol), L-
ascorbic acid (0.114 g, 0.65 mmol), and 
DMF/piperidine (8/2) at 25 °C for 6 h.[11]  
The resin was washed with 5 × 5 mL 
Et2NCSSNa•3H2O (sodium diethyldithio-
carbamate trihydrate, 1% w/v), containing 
1% DIEA (v/v) in DMF to remove the 
coordinated copper from click reaction.[12] 
SCHEME S2. 
The biligand anchor (D-Pra)-
kwlwGl-Tz1-kfwlkl was synthesized on 2-
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chlorotrityl chloride (1.6 mmol/g) resin (Anaspec, San Jose, CA) using Scheme S2.  The biligand 
anchor was released either as the fully deprotected peptide by cleavage with 95:5 TFA:water (+ 2 
mol equiv TES per side chain protecting group), or as the fully protected peptide by cleavage 
with 99:1 DCM:TFA.[13]  To facilitate the on-bead click reaction, it is noted that the 1° ligand 
was synthesized here as Az4-kfwlkl (displaying N-terminal Azn modification), and to this 
sequence was coupled D-Pra and the 2° ligand to produce the linear biligand. 
Triligands were synthesized by click reaction between the fully protected biligand anchor 
(0.274 g, 0.1 mmol, >98% HPLC) and bead-bound 3° ligand Az4-nlivfr (0.1 g, 0.03 mmol) 
using CuI (0.021 g, 0.1 mmol) and L-ascorbic acid (0.020 g, 0.1 mmol) in DMF/piperidine (8/2). 
 
TYPICAL SCREENING PROCEDURES 
A typical screen began with a library incubation in PBS (pH 7.4) + 0.1% Tween 20 + 
0.1% bovine serum albumin (BSA) + 0.05% NaN3 (PBSTBNaN3) for 1 h, with shaking, to block 
non-specific protein binding.[14]  The library was then washed with 3 × 5 mL PBSTBNaN3.  On-
bead multi-ligand screens were conducted at an appropriate bCAII-Alexa Fluor 647 dilution 
(Table S2), and then washed with 3 × 5 mL PBSTBNaN3, 3 × 5 mL PBS (pH 7.4) + 0.1% Tween 
20, and finally 6 × 5 mL PBS (pH 7.4).  All in situ screens contained an additional 2 h pre-
incubation of bCAII-Alexa Fluor 647 with anchor ligand (≥2000 equiv, relative to protein), after 
which the bead library was added to this mixture and the screen was continued (Table S2).  
Following in situ screening, beads were washed with 3 × 5 mL PBSTBNaN3, 3 × 5 mL PBS (pH 
7.4) + 0.1% Tween 20, and then 6 × 5 mL PBS (pH 7.4). 
Screened beads were transferred onto a glass microscope slide and immediately imaged 
for fluorescence using a GenePix 4200 array scanner (λex = 635 nm).  The hit beads were 
selected manually by glass micropipette.  To remove bound proteins, each hit bead was 
incubated in 7.5 M guanidine hydrochloride (pH 2.0) for 1 h, followed by ten rinses with water. 
Edman sequencing of single hit beads was carried out on a Model 494 Procise cLC 
Sequencing System (Applied BioSystems, Foster City, CA).  Iterative N-terminal chemical 
degradation cycles yielded direct positional amino acid information.  Each degradation cycle 
produced one PTH-amino acid (PTH = phenylthiohydantoin) product that was analyzed by 
HPLC and identified by retention time as compared with PTH-amino acid standards. 
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 Table S2.  Screening summary.  All screens at pH = 7.4 and T = 25 oC, unless otherwise noted.  
Screen Library [bCAII-
AF647] 
Time(h) % hit beads Buffer Other 
components 
An1 A 100 nM 1 h 0.02% PBS   
An2a B 50 nM 1 h 0.09% PBS   
An2b B 8 nM 24 h 2 hits PBS   
Bi1 C 50 nM 2 h; 37o (no 
beads) + 48 
h; 37o 
0.007% PBS + 1% 
DMSO (v/v) 
100 µM of lklwfk-
(D-Pra) 
Bi2a D 50 nM 17 h 0.07% PBSTBNaN3   
Bi2b D 10 nM 17 h 0.008% PBSTBNaN3   
Tri1 C 10 nM 2 h (no 
beads) +15 h 
0.007% PBSTBNaN3 + 
1% DMSO (v/v)   
100 µM of (D-
Pra)-kwlwGl-
Tz1-kfwlkl 
Tri2 E 10 nM 17 h 0.008% PBSTBNaN3   
TriX A 10 nM 17 h 0.007% PBSTBNaN3 + 
1% DMSO (v/v)   
100 µM of (D-
Pra)-kwlwGl-
Tz1-kfwlkl 
Tri3 F 0.5 nM 2 h (no 
beads) +18 h 
0.005-0.01% PBSTBNaN3 + 
1% DMSO (v/v)   
100 µM of (D-
Pra)-kwlwGl-
Tz1-kfwlkl 
Tri4 G 0.25 nM 18 h 0.005-0.01% PBSTBNaN3   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S8 
S9 
COMPLETE HIT SEQUENCING RESULTS:  Tables S3-S13 
  
Table S3.  First-generation anchor ligand screen An1 results. 
 
x1 x2 x3 x4 x5 
hit1 r r y h r 
hit2 m/v r w k r 
hit3 k r w y y 
hit4 w k k k w 
hit5 h f f f r 
hit6 s r -- r r 
hit7 r r w h y 
hit8 r k w w w 
hit9 r w s f r 
hit10 r r g w r 
hit11 g f r r w 
hit12 r t r r w 
hit13 m r w k r 
hit14 y r k r w 
hit15 a -- -- -- -- 
hit16 r r i r w 
hit17 -- -- k/l w -- 
hit18 r w -- -- r 
hit19 k/l r -- w r 
hit20 w r f r y 
hit21 d/p y y r r 
hit22 r y w k k 
hit23 k/l r r r w 
hit24 y r r k w 
hit25 r k/l f y r 
hit26 r w w k r 
 x1 x2 x3 x4 x5 
hit27 w r -- y r 
hit28 h r w r r 
hit29 w y r k r 
hit30 l r f r r 
hit31 w k r k k 
hit32 r r r w s/m 
hit33 r r k f w 
hit34 r r w r y 
hit35 w r h y k 
hit36 r r y f r 
hit37 w r k w r 
hit38 w y -- r r 
hit39 y r r r h 
hit40 y r r r w 
hit41 p f y w r 
hit42 k y w r k 
hit43 r y w h k 
hit44 r w h w n 
hit45 r h f h h/f 
hit46 r r -- h r 
hit47 r y r r r 
hit48 y f h h/w w 
hit49 r r r w y 
hit50 w r r r r/-- 
hit51 r w k f h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4.  Second-generation anchor ligand screen An2a results. 
 
 x1 x2 x3 x4 x5 x6 
hit1 y r w f k f 
hit2 h/r h/r f l l/r r 
hit3 f r f y y r 
hit4 h/r f f k l -- 
hit5 k l f l k l 
hit6 l f l w l k 
hit7 f f f r y -- 
hit8 h/r f f f r -- 
hit9 r w w l k f 
hit10 h/r f f r y y 
hit11 l k l f l k 
hit12 f r r w w k 
hit13 h/r y f f k l 
hit14 l k f f f k 
hit15 h/r f f r r -- 
 
 
Table S5.  Second-generation anchor ligand screen An2b results. 
 
 x1 x2 x3 x4 x5 x6 
hit1 h l y f l r 
hit2 l k l w f k 
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Table S6.  In situ biligand screen Bi1 results. 
 
 Azn x2 x3 x4 x5 x6 Azn 
hit1 Az4 k i w i G   
hit2 Az8 r l w v G Az4 
hit3 Az8 r r r k r Az8 
hit4 Az4 l l v i k Az4 
hit5 Az4 m i l i k   
hit6 Az8 i i i m r Az4 
hit7 Az8 i i i w r Az8 
hit8 Az4 n v i i f   
hit9 Az4 i f l v k Az8 
hit10 Az4 k i w i G Az8 
hit11 Az4 r r k f r Az8 
hit12 Az4 r v w l r Az8 
hit13 Az8 k y r r r Az4 
hit14 Az8 r r k v w Az4 
hit15 Az4 i f l v k Az8 
hit16   k r k r f Az4 
hit17 Az8 k i w i k   
hit18 Az8 y r k f k   
hit19 Az4 i f f r v Az8 
hit20   a r k k y Az4 
hit 21   r k r t i Az4 
hit 22 Az8 k m v f k Az4 
hit23 Az4 l i m k i Az4 
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Table S7.  On-bead biligand screen Bi2a results. 
 
  x1 x2 x3 x4 x5 x6 
hit1 f k l w i k 
hit2 v w l w G G 
hit3 f w f w G G 
hit4 k w f w G G 
hit5 f k l w l k 
hit6 k w f w G G 
hit7 w w i w G G 
hit8 k G w l w G 
hit9 k l w i w G 
hit10 l w i w G l 
hit11 f k G f l i 
hit12 f w i w G k 
hit13 l w l w G i 
hit14 i i v l w k 
hit15 l i i f v  
hit16 v k f i l l 
hit17 l G f f w i 
hit18 k k l k k l 
hit19 f k l w i k 
hit20 w i w G G f 
hit 21 f f l l v k 
hit 22 k f k f w k 
hit23 l i k l f v 
hit24 l w f w G v 
hit25 f w f w G i 
hit26 G w f w G v 
hit27 G w i w G k 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S8.  On-bead biligand screen Bi2b results. 
 
 x1 x2 x3 x4 x5 x6 
hit1 k w i w G w 
hit2 k w i w G v 
hit3 k w l w G l 
hit4 k w i w G l 
hit5 k w i w G w 
hit6 k w l w G l 
hit7 G w i w G i 
hit8 k i f k i f 
 
 
S12 
S13 
Table S9.  First-generation in situ triligand screen Tri1 results. 
 
 Azn x2 x3 x4 x5 x6 Azn 
hit1 Az4 n i i i v  
hit2 Az4 i i l l k Az4 
hit3 Az4 n i i v l  
hit4 Az4 n m i f l Az4 
hit5 Az4 n v l v l  
hit6 Az4 n l i l f Az4 
hit7 Az4 n l i l f Az4 
hit8 Az8 r l w i r Az4 
hit9 Az4 n l i v f Az4 
hit10 Az4 r m w v k Az8 
hit11 Az4 i i l l k Az8 
hit12 Az4 i l v v r Az4 
hit13 Az4 n l l f l Az4 
hit14 Az4 n i i v y  
hit15  m k r k k Az8 
hit16 Az4 i l i r w Az4 
hit17 Az8 i i v f r Az8 
hit18 Az8 y f t r r  
hit19 Az4 n m i i v Az4 
hit20 Az8 i l i a k Az4 
hit21 Az4 i l l r w  
hit22 Az8 i v v f r Az4 
hit23 Az4 l l l v k Az4 
hit24 Az4 k v w i k Az4 
hit25 Az4 i m v l r Az4 
 
 
Table S10.  First-generation on-bead triligand screen Tri2 results. 
 
 x2 x3 x4 x5 x6 x7 
hit1 r l w l r f 
hit2 r l w l r l 
hit3 r f f f r f 
hit4 r l f l r f 
hit5 l f f w f r 
hit6 l w f f f r 
hit7 l f l w f r 
hit8 l w l f f r 
hit9 l f f w l r 
hit10 r r r l w r 
hit11 r l w l r f 
hit12 w r r r r w 
hit13 r f r f r w 
hit14 f w f f w r 
 
 
Table S11.  Second-generation in situ triligand screen Tri3 results. 
 
 x2 x3 x4 x5 x6 x7 
hit1 n l i v f r 
hit2 n l i v l r 
hit3 n i i l l r 
hit4 i l f l f r 
hit5 n l i v l r 
hit6 n i i l w r 
hit7 n l i v f r 
hit8 n l i v f r 
 
 
Table S12.  Second-generation on-bead triligand screen Tri4 results. 
 
 x2 x3 x4 x5 x6 x7 
hit1 n l i v f r 
hit2 n l i v f r 
hit3 n i i v f r 
hit4 n i i v f r 
hit5 n i i l l r 
hit6 n l i v l r 
hit7 n l i v f r 
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Table S13.  Azide-free in situ triligand screen TriX results (control). 
 
x1 x2 x3 x4 x5 
hit1 w f r r r 
hit2 s w v w G 
hit3 p v y f w 
hit4 d d y w G 
hit5 i w a y w 
hit6 d n w G f 
hit7 a w w a t 
hit8 r f r r f 
hit9 d w w h t 
hit10 r f r w r 
hit11 d e w p h 
hit12 a w w l w 
hit13 a w w a y 
hit14 d k k i y 
hit15 d w s i e 
hit16 s w w f y 
hit17 d w l r y 
hit18 s w a f y 
hit19 d l f l w 
hit20 d w a t w 
hit21 f k y r s 
hit22 d q r w r 
hit23 i w s t h 
hit24 l i v m w 
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BILIGANDS AND TRILIGANDS REPORTED:  Figures S1-S6 
 
 
 
 
Figure S1.  Triligand (Mol. Wt. 3045.72), used in SPR measurement of affinity. 
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Figure S2.  Triligand, biotin conjugate (Mol. Wt. 3475.29), used in dot blot experiments. 
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Figure S3.  Biligand Anchor, deprotected (Mol. Wt.: 2131.61), used for in situ screens. 
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Figure S4.  Biligand Anchor, fully protected (Mol. Wt.: 2732.30), used in bulk triligand 
synthesis. 
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Figure S5.  Biligand Anchor, biotin conjugate (Mol. Wt.: 2651.26), used in dot blot experiments 
and assays for detecting on-bead, protein-templated multi-ligand. 
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Figure S6.  Biligand kwlwGl-Tz1-kfwlkl (Mol. Wt.: 1993.49), used in SPR measurement of 
affinity. 
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CUSTOM EDMAN DEGRADATION 
To allow for resolution of artificial azide-containing amino acids by Edman degradation, 
the Pulsed-Liquid cLC extended method was utilized (Figure S7).  It includes a modified 
gradient, Normal 1 cLC extended (Figure S8), and a flask cycle extended by 5 min (Flask 
Normal extended, Figure S9). 
The Edman traces corresponding to elution of Az2, Az4, Az6 and Az8 are shown in 
Figure S10 and demonstrate a 6-min retention time increase for every two methylene units added 
to the azidoalkyl side chain.  Fmoc-Az2-OH was synthesized according to literature protocol,[15] 
while Fmoc-Az6-OH was synthesized according to Scheme S1. 
 
 
Figure S7.  Pulsed-Liquid cLC extended method. 
 
 
Figure S8.  Normal 1 cLC extended gradient. 
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Figure S9.  Final steps of Flask Normal extended flask cycle. 
 
 
Figure S10.  Edman traces for artificial azide-containing amino acids. 
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AFFINITY MEASUREMENTS 
Fluorescence polarization.  The N-terminus of the anchor ligand was labeled with 
fluorescein isothiocyanate (FITC) following published protocols.[16]  After resin cleavage, the 
crude fluoresceinated anchor ligand was precipitated with ether and then purified to >98% by C18 
reversed phase HPLC. 
Luminescence spectra were recorded by Fluorolog2 spectrofluorimeter (Jobin Yvon, 
Longjumeau, France).  All samples contained 6 μM fluoresceinated anchor ligand and varying 
concentrations of bCAII (0.2 μM to 800 μM) in PBS (pH 7.4) + 3% (v/v) DMSO.  Stock protein 
and anchor ligand concentrations were verified by UV-Vis using ε280 (bCAII) = 57,000 M-1cm-1 
or ε494 (FITC, 0.1 N NaOH) = 68,000 M-1cm-1 for fluoresceinated anchor ligand.  Samples were 
excited at 488 nm (2-nm band-pass), and luminescence spectra were obtained between 500 nm 
and 700 nm (4-nm band-pass).  All measurements were taken at 2-nm intervals with 0.5 s 
integration times at 25 °C.  All luminescence spectra were subjected to background subtraction. 
The ratio of sensitivities (G) for the vertically and horizontally plane-polarized light in 
the system was calculated by the equation G=IHH/IHV using the IHH and IHV luminescence spectra 
obtained from a peptide-only sample.  The luminescence spectra IVV and IVH were integrated, and 
the fluorescence polarization value (P) 
was obtained by applying Equation 1. 
 
Figure S11.  Fluorescence polarization binding 
isotherm for the anchor ligand lklwfk-(D-Pra), 
showing KD ≈ 500 μM.  For fluorescence polarization 
experiments, the anchor ligand was labeled with 
FITC at the N-terminus.  All samples contained 6 μM 
FITC-anchor ligand and varying concentrations of 
bCAII (0.2 μM to 800 μM). 
VHVV
VHVV
GII
GII
P +
−
              (1) =
Polarization values were fitted with a 
sigmoidal dose-response curve.  Figure 
S11 shows that the anchor ligand 
lklwfk-(D-Pra) exhibited ~500 μM 
affinity to bCAII. 
 
 Surface plasmon resonance 
(SPR).  These affinity measurements 
utilized a Biacore T100 SPR (Caltech 
Protein Expression Center).  One flow 
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cell of the biosensor surface (Biacore CM5) was 
immobilized with bCAII following standard 
procedures using 0.25 mg/mL bCAII prepared in 10 
mM sodium acetate (pH 5.0) buffer and a 1:1 
solution of 0.1 mM NHS and 0.4 mM EDC.[17]  
Similarly, a second flow cell was immobilized with 
hCAII following standard procedures using 0.25 
mg/mL hCAII prepared in 10 mM sodium acetate 
(pH 5.5) buffer.[18]  Immobilization levels of ~4000 
RU were achieved using a flow rate of 100 µl/min 
over 420 s.  The remaining two flow cells were left 
underivatized, to correct for changes in bulk 
refractive index and to assess non-specific binding.  
The running buffer was prepared to contain 10 mM 
HEPES + 150 mM NaCl + 0.05% Tween20 + 3% 
DMSO, and this buffer was used for all 
experiments. 
Prior to the peptide analyte experiment, 8 
buffer-alone cycles were completed to establish 
baseline stabilization.  Response data were then 
collected for anchor, biligand, or triligand peptide 
samples over varying concentrations at 100 μL/min 
flow rate, 120-180 s contact time, and 300 s 
dissociation phase across the four flow cells.  
Following background subtraction, the analyte 
response data was fitted for 1:1 binding affinity 
using the BiaEvaluation software.  In Figure S12, representative results are shown for biligand 
(a) and triligand (b, c). 
 
Figure S12.  (a) SPR response 
sensorgrams obtained with increasing 
concentration of the biligand kwlwGl-
Tz1-kfwlkl (2 nM to 5 µM) demonstrate a 
3-μM biligand affinity to bCAII. For the 
triligand (rfviln-Tz2-kwlwGl-Tz1-kfwlkl), 
SPR response sensorgrams were 
obtained with increasing peptide 
concentration (0.1 nM to 162 nM) and 
demonstrate 45-nM and 64-nM affinities 
for human (b) and bovine (c) CA II, 
respectively. 
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ENZYMATIC ACTIVITY ASSAY IN THE PRESENCE OF TRILIGAND 
 The active site of bCAII possesses an intrinsic esterase activity which can be monitored 
spectrophotometrically.  Specifically, bCAII catalyzes the hydrolysis of 4-nitrophenyl acetate (4-
NPA) to 4-nitrophenol (4-NP), whose appearance can be monitored by absorbance at 400 nm.[19]  
The enzyme-catalyzed hydrolysis proceeds at a range of pH and serves as a test for active site 
binding by common inhibitors (Scheme S3).  Here, this activity assay was used to determine 
whether the triligand capture agent interferes with bCAII esterase activity, which would suggest 
active site binding by the triligand.  Solution assays were 200 µL in volume, containing 1.4 µM 
bCAII, 5 µM triligand, and 50 µM 4-NPA in Tris buffer composed of 9 mM Tris-HCl and 81 
mM NaCl + 9% acetonitrile (v/v) + 1% DMSO (v/v).  Control assays were conducted in the 
absence of triligand, and in the absence of protein.  The hydrolysis of 4-NPA was monitored over 
a time course of 60 minutes, with absorbance measurements taken every 6 minutes. 
 
 
Figure S13.  Enzymatic activity of bCAII in 
the presence of triligand.  Absorbance data 
monitor the bCAII-catalyzed hydrolysis of 4-
NPA to 4-NP (ε = 18,400 M-1cm-1 at 400 nm) 
at the protein active site.  Experiments were 
performed with (red) and without (black) 
triligand capture agent.  Additionally, an 
assay was performed in the presence of 4-
NPA alone (blue) to determine the slow 
background hydrolysis of the ester in 
aqueous solution.  [bCAII] = 1.4 µM, 
[Triligand] = 5 µM, and [4-NPA] = 50 µM in 
Tris buffer [9 mM Tris-HCl, 81 mM NaCl, 9% 
acetonitrile (v/v),1% DMSO (v/v)]. 
 
Scheme S3.  Esterase activity of bCAII, using 
4-NPA as the hydrolytic substrate. 
 
The experimental results are presented 
in Figure S13.  We observed that there was an 
initial “burst” in 4-NP formation, followed by 
a slow increase in the product formation over 
the 60 min.  Because there was no appreciable 
change in the bCAII esterase activity when the 
triligand capture agent was included in the 
assay, apparently this peptide binds to an 
epitope distinct from the bCAII active site. 
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DOT BLOT SELECTIVITY/SENSITIVITY ASSAYS IN SERUM 
The sensitivity and selectivity of the multi-ligand (biligand and triligand) capture agents 
for b(h)CAII in complex environments were demonstrated through the use of dot blot 
experiments in 10% porcine serum.  For these tests, Biotin-PEG-NovaTag resin (0.48 mmol/g; 
Novabiochem) was utilized for bulk synthesis of C-terminal biotin-labeled multi-ligands.  After 
resin cleavage, the crude biotinylated multi-ligand was precipitated with ether and then purified 
to >98% by C18 reversed phase HPLC. 
b(h)CAII antigens were prepared as 1 mg/mL stocks in PBS (pH 7.4).  A dilution series 
of antigen was applied to a nitrocellulose membrane, typically ranging from 2 µg to 0.5 ng per 
spot.  The membrane was blocked at 4 °C overnight in 5% milk in Tris-buffered saline (TBS) 
[25 mM Tris, 150 mM NaCl, 2 mM KCl (pH 8.0)].  The membrane was then washed with TBS.  
The biotinylated multi-ligand was prepared at 1 µM in 10% porcine serum in TBS + 0.1% 
DMSO (v/v) and incubated over the membrane overnight at 4 °C.  After washing with TBS for 1 
h, 1:3000 Streptavidin-HRP (Abcam, Cambridge, MA) prepared in 0.5% milk/TBS was added to 
the membrane and incubated for 1 h.  After washing with TBS for 1 h, the membrane was treated 
to chemiluminescent reagents (SuperSignal West Pico Chemiluminescent Enhancer and 
Substrate Solutions, Pierce, Rockford, IL) and then immediately developed on film. 
 
ON-BEAD DETECTION OF IN SITU TRIAZOLE FORMATION 
 A biotin conjugate of the biligand anchor was prepared by modifying the N-terminus 
with an ethylene glycol linker (Fmoc-NH-(PEG)5-COOH, EMD Biosciences) followed by biotin, 
by standard SPPS.  A stock solution of this biotinylated biligand anchor Biotin-(EG)5-(D-Pra)-
kwlwGl-Tz1-kfwlkl (1.25 mM, alkyne) was prepared in DMSO (EG = ethylene glycol).  Stock 
solutions of bCAII (30 µM) and hCAII (30 µM) were prepared in 50 mM Tris-Cl buffer (pH 
7.2).  For control experiments, stock solutions of human transferrin (Tf, 30 µM) and BSA (30 
µM) were prepared in 50 mM Tris-Cl buffer (pH 7.2), and Biotin-RPRAAA-Pra (1.25 mM, 
alkyne with no documented affinity for CA II) was prepared in DMSO.  The consensus 3° ligand 
Az4-nlivfr (azide) was synthesized in bulk on TentaGel S-NH2 beads.  Each in situ reaction 
contained 0.5 mg beads appended with 3° ligand, 30 μM biotinylated peptide-alkyne, and 15 μM 
protein in a final volume of 50 μL 50 mM Tris-Cl buffer (pH 7.2) + 2.5% DMSO (v/v).  In situ 
click reactions proceeded for 24 h at 25 °C with shaking.  Reactions were quenched with 50 μL 
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7.5 M guanidine hydrochloride (GuHCl, pH 2.0).  Following incubation with GuHCl (pH 2.0) 
for 1 h, the beads were washed with 10 × 200 µL water, leaving only covalently bound peptides 
(3° ligand and biotinylated in situ triligand) on the bead. 
 To prepare for the enzyme-linked, colorimetric assay,[20] beads were washed with 3 × 100 
µL Blocking Buffer (25 mM Tris-Cl, 10 mM MgCl2, 150 mM NaCl, 14 mM 2-mercaptoethanol, 
0.1% (w/v) BSA, 0.1% (v/v) Tween 20, pH 7.5).  Beads were then incubated in Blocking Buffer 
for 1 h with shaking.  Alkaline phosphatase-streptavidin (AP-SA, Promega) was introduced at 
1:300 dilution in Blocking Buffer to bind to any potential bead-bound biotinylated triligand.  
This AP-SA solution was incubated for 1 h with shaking.  Excess AP-SA was then removed by 
washing the beads with 3 × 300 µL Wash 1 Buffer (25 mM Tris-Cl, 10 mM MgCl2, 150 mM 
NaCl, 14 mM 2-mercaptoethanol, pH 7.5), followed by 2 × 250 µL Wash 2 Buffer (25 mM Tris-
Cl, 14 mM 2-mercaptoethanol, pH 7.5).  Beads were developed for 2 h in 50 µL of the 
chromogenic substrate BCIP (5-bromo-4-chloro-3-indoyl phosphate, Promega). 
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